Interferon alpha and its contribution to autoimmunity - PubMed (original) (raw)
Affiliations
- PMID: 16729722
Review
Interferon alpha and its contribution to autoimmunity
Carlo Selmi et al. Curr Opin Investig Drugs. 2006 May.
Abstract
It is now well accepted that interferon (IFN)alpha plays a critical role in the pathogenesis and perpetuation of specific autoimmune diseases, including systemic lupus erythematosus (SLE), autoimmune thyroid disease and type 1 diabetes. IFNalpha-based treatments are widely used for the treatment of chronic viral infections, particularly chronic hepatitis C virus infection; however, several case reports have emerged describing autoimmune conditions that have developed during IFNalpha therapy. The data support the pathogenic potential of IFNalpha in autoimmunity, although it is clear that genetic and environmental factors are also key to the development of autoimmune conditions. Several points of interaction between IFNalpha and immune effector cells have been experimentally defined, the functional consequences of many of which remain poorly understood. This review describes the most recent data in support of an important role for IFNalpha in autoimmunity, particularly SLE, and the potential mechanisms by which IFNalpha contributes to immune dysfunction. Future approaches to IFNalpha modulation as a therapeutic strategy for use in the treatment of autoimmune diseases are also discussed.
Similar articles
- Autoimmune manifestations during interferon therapy in patients with chronic hepatitis C: the hepatologist's view.
Pellicano R, Smedile A, Peyre S, Astegiano M, Saracco G, Bonardi R, Rizzetto M. Pellicano R, et al. Minerva Gastroenterol Dietol. 2005 Mar;51(1):55-61. Minerva Gastroenterol Dietol. 2005. PMID: 15756146 - Systemic lupus erythematosus and Sjögren's syndrome induced in a case by interferon-alpha used for the treatment of hepatitis C.
Onishi S, Nagashima T, Kimura H, Matsuyama Y, Yoshio T, Minota S. Onishi S, et al. Lupus. 2010 May;19(6):753-5. doi: 10.1177/0961203309353172. Epub 2010 Jan 11. Lupus. 2010. PMID: 20064909 - Syndromes and complications of interferon therapy.
Borg FA, Isenberg DA. Borg FA, et al. Curr Opin Rheumatol. 2007 Jan;19(1):61-6. doi: 10.1097/BOR.0b013e328010c547. Curr Opin Rheumatol. 2007. PMID: 17143098 Review. - Interferon alpha and neuromuscular disorders.
Stübgen JP. Stübgen JP. J Neuroimmunol. 2009 Feb 15;207(1-2):3-17. doi: 10.1016/j.jneuroim.2008.12.008. Epub 2009 Jan 25. J Neuroimmunol. 2009. PMID: 19171385 Review. - Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjögren's syndrome autoantigen-associated RNA.
Lövgren T, Eloranta ML, Kastner B, Wahren-Herlenius M, Alm GV, Rönnblom L. Lövgren T, et al. Arthritis Rheum. 2006 Jun;54(6):1917-27. doi: 10.1002/art.21893. Arthritis Rheum. 2006. PMID: 16729300
Cited by
- Structural Insights into the Neutralization Properties of the Fully Human, Anti-interferon Monoclonal Antibody Sifalimumab.
Oganesyan V, Peng L, Woods RM, Wu H, Dall'Acqua WF. Oganesyan V, et al. J Biol Chem. 2015 Jun 12;290(24):14979-85. doi: 10.1074/jbc.M115.652156. Epub 2015 Apr 29. J Biol Chem. 2015. PMID: 25925951 Free PMC article. - Neutralizing type I IFN antibodies trigger an IFN-like response in endothelial cells.
Moll HP, Freudenthaler H, Zommer A, Buchberger E, Brostjan C. Moll HP, et al. J Immunol. 2008 Apr 15;180(8):5250-6. doi: 10.4049/jimmunol.180.8.5250. J Immunol. 2008. PMID: 18390705 Free PMC article. - Determination of paraneoplastic autoimmune responses by tumor cell biology and intratumoral IFN-alpha/IL-12 in breast cancer patients.
Domschke C, Schuetz F, Ge Y, Rom J, Zorn M, Sinn HP, Marmé F, Schott S, Heil J, Scharf A, Sohn C, Schneeweiss A, Beckhove P. Domschke C, et al. Cancer Immunol Immunother. 2011 Mar;60(3):401-11. doi: 10.1007/s00262-010-0956-4. Epub 2010 Dec 14. Cancer Immunol Immunother. 2011. PMID: 21161218 Free PMC article. - Interferon-induced protein IFIT4 is associated with systemic lupus erythematosus and promotes differentiation of monocytes into dendritic cell-like cells.
Huang X, Shen N, Bao C, Gu Y, Wu L, Chen S. Huang X, et al. Arthritis Res Ther. 2008;10(4):R91. doi: 10.1186/ar2475. Epub 2008 Aug 15. Arthritis Res Ther. 2008. PMID: 18706081 Free PMC article. - RNase L contributes to experimentally induced type 1 diabetes onset in mice.
Zeng C, Yi X, Zipris D, Liu H, Zhang L, Zheng Q, Malathi K, Jin G, Zhou A. Zeng C, et al. J Endocrinol. 2014 Dec;223(3):277-87. doi: 10.1530/JOE-14-0509. Epub 2014 Oct 6. J Endocrinol. 2014. PMID: 25287058 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical